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Severe cases of postprandial hypoglycaemia after bariatric surgery can be a diagnostic and therapeutic challenge. (e diagnostic
role of 68Ga-DOTA-Exendin-4 PET/CT in postbariatric hypoglycaemia for further treatment decisions is unclear. We present a
case of a 50-year-old woman with frequent and severe postprandial hypoglycaemic (≤2.5mmol/L) episodes starting three years
after Roux-Y gastric bypass. Despite strict dietary adherence and several medical therapies, the patient remained severely affected,
and 68Ga-DOTA-Exendin-4 PET/CT was performed to exclude atypical presentation of an insulinoma or nesidioblastosis. No
pancreatic abnormalities were found, but intensive tracer accumulation in the first and second part of the duodenumwas detected,
which proved to be hyperplastic Brunner’s glands on histology and were strongly positive for the glucagon-like peptide-1 receptor.
(is case provides histopathological verification that duodenal 68Ga-DOTA-Exendin-4 uptake is caused by uptake in Brunner’s
glands and points to a potential relationship between bariatric surgery and Brunner’s glands.
1. Introduction
Postbariatric hypoglycaemia (PBH), formerly also described
as late dumping, is a significant but under-recognized
medical complication after bariatric surgery [1, 2].
Depending on the diagnostic test, recent data suggest higher
incidence rates than previously thought, occurring in up to
48% of patients after Roux-Y gastric bypass and up to 25% of
patients after sleeve gastrectomy [3–5]. (e characteristic
hallmark of PBH is a rapid increase in blood glucose shortly
after ingestion of carbohydrates followed by increased in-
sulin secretion, resulting in postprandial symptomatic
hypoglycaemia [1]. (e exact mechanisms of PBH have not
been fully elucidated, and thus, no approved medical
treatment exists so far. Patients, uncontrolled with dietary
modifications, are often treated with off-label medications
according to individual case-finding strategies [1, 6]. Based
on controversial data suggesting an increase in β-cell mass or
even development of nesidioblastosis, some severely affected
patients were reported to be either anatomically reverted or
(hemi)pancreatectomized with varying success rates [6].
For patients with other forms of endogenous hyper-
insulinaemic hypoglycaemia, such as insulinoma or adult
nesidioblastosis [7], glucagon-like peptide-1 receptor (GLP-
1R) imaging using 68Ga-DOTA-Exendin-4 PET/CT has been
reported to be very useful in localizing the insulinomas or
focal nesidioblastosis [7, 8]. However, in vitro data using
autoradiography in pancreatectomized patients with severe
PBH indicate that the density of GLP-1R is not increased in
islets compared to normal islets and is significantly lower than
that in insulinomas [9]. GLP-1R imaging may, therefore, not
be useful in patients with PBH to prove possible
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nesidioblastosis in PBH. Nevertheless, GLP-1R imaging in
vivo has not yet been reported in patients with PBH.
2. Case Presentation
A 50-year-old woman was admitted to our outpatient clinic
for medical workup of a severe form of postprandial hypo-
glycaemia. Seven years earlier, a Roux-Y gastric bypass was
performed due to morbid obesity (preoperative BMI 44.7 kg/
m2and weight 129 kg). Within two years, the patient lost
57 kg (BMI 25.5 kg/m2). A year later, the patient noticed, for
the first time, hypoglycaemic episodes 1-2 hours after meal
intake, which were mainly characterized by loss of con-
centration, severe fatigue, and auditory and visual impairment
that quickly resolved after intake of carbohydrates. An oral
glucose tolerance test, at that time, confirmed the presence of
symptomatic postprandial hypoglycaemia (2.9mmol/l).
Symptoms persisted despite dietary modifications of up to
twelve small meals, each containing a maximum of 20 g of
carbohydrates. Off-label treatment with acarbose, saxagliptin,
and metformin by her treating physician reduced the fre-
quency and severity of hypoglycaemic episodes but did not
significantly improve the situation. Eventually, the patient was
referred to our hospital. Her remaining personal history
included a mild form of orthostatic dysregulation, migraine,
and amultilocular nodular hepatic hyperplasia that required a
left-sided hemihepatectomy 17 years ago. (e clinical ex-
amination was unremarkable apart from irritation-free scars
after hemihepatectomy (height, 168 cm; weight, 72 kg; BMI,
25.5 kg/m2; blood pressure, 127/67mmHg; regular heartbeat,
80 bpm). Laboratory analysis including blood smear; bio-
chemistry comprising electrolytes and kidney and liver pa-
rameters; glycated haemoglobin; blood lipids; iron; vitamins
B1, B6, B12, and D; and zinc were within reference ranges. A
continuous glucose flash monitoring system confirmed a
typical pattern of postbariatric hypoglycaemia without any
signs of fasting or nocturnal hypoglycaemia. A mixed-meal
test (300ml Ensure plus®) containing 60 g of carbohydratesafter a 10-hour fasting period confirmed symptomatic
postprandial hypoglycaemia (sweating, drowsiness, odd be-
haviour, and incoordination) at a glucose level of 2.5mmol/l,
and intravenous glucose administration was required for
immediate remission of symptoms (Figure 1(a)). Due to the
severe symptomatic presentation of the patient, a 68Ga-
DOTA-Exendin-4 PET/CT was performed to exclude an
atypical presentation of an insulinoma or focal nesidio-
blastosis, which might be a surgical target [10–12]. (erein,
the pancreas showed a homogeneous signal distribution (SUV
5.7–8.3), but intensive uptake in the first and second part of
the duodenum (SUVmax of 10.0) was observed (Figure 1(b)).
To further differentiate this unexpectedly strong tracer ac-
cumulation, a double-balloon enteroscopy was performed,
which revealed macroscopically unremarkable intraluminal
structures in the duodenum. Histologically, there were no
signs of malignancy or inflammation (Figure 1(c)). Repre-
sentative biopsies of the pars 2 duodenii showed normal
mucosa with hyperplastic Brunner’s glands, which were
strongly positive for the GLP-1 receptor on immunohisto-
chemistry but negative for insulin (Figures 1(d) and 1(e)).
3. Discussion
(is is the first case of PBH with a histologically proven
GLP-1R-mediated increase in 68Ga-DOTA-Exendin-4 up-
take in hyperplastic Brunner’s glands of the duodenum.
A complex interplay of several factors is important for
the development of PBH rather than a dominant single
factor [1]. One pivotal factor is the glucagon-like peptide-1
(GLP-1) concentration, which is significantly increased in
patients after bariatric surgery and specifically in those
patients with PBH [2, 13, 14]. Antagonizing its effect by
using exendin 9–39 lowers the rate of PBH [15]. However,
there are also reports of successful treatment with GLP-1
agonists [16], but data on its mechanisms still need to be
unravelled [17]. (ere is currently no commercially and
medically approved compound available for the treatment of
PBH [1]. On the other hand, GLP-1R imaging is a new
molecular imaging method that is useful for the localization
of insulinomas and eventually adult nesidioblastosis in
patients with endogenous hyperinsulinaemic hypoglycaemia
(EHH) [7, 8]. (e physiological background relies on high
expression levels of GLP-1R in benign insulinomas and adult
nesidioblastosis. Studies using autoradiography indicate that
normal pancreatic islets express approximately six times less
GLP-1R than insulinomas [9, 18, 19].
(e hyperplasia of Brunner’s glands and high accu-
mulation of 68Ga-DOTA-Exendin-4 in those Brunner’s
glands resulting in a positive GLP-1R PET/CT scan
(Figure 1(b)) is a surprising finding. (e underlying path-
ophysiological mechanism is unclear. Brunner’s glands are
mucinous glands that are primarily located in the proximal
duodenum, where their glycoprotein-rich mucus serves as a
protective barrier for underlying structures against acidic
and pepsin-containing agents from the stomach. Incretins
(glucagon, GLP-1, vasoactive intestinal peptide, secretin,
and cholecystokinin) and neuronal factors (acetylcholine)
stimulate mucus and bicarbonate secretion from the glands
[20]. (ese glands have been convincingly shown in vitro to
express GLP-1R in high density and with a strong mem-
branous pattern via immunohistochemistry staining,
reflecting the localization of this G-protein coupled receptor,
as depicted in Figure 1(d) [19, 21]. Duodenal GLP-1R ap-
pears to be important for neuro-glucoregulation and gut-
lipid-sensing [22]. Recent data also suggest a role for
pathogen defence, mucosal layer protection, and mucosal
healing by targeting GLP-1R in Brunner’s glands [23].
Whether these murine data translate to humans and whether
ligands other than GLP-1 play a role remain uncertain [24].
It is conceivable that in patients with PBH, increased GLP-1
levels but also other incretins such as GLP-2 with trophic
effects may also lead to hyperplasia of Brunner’s glands, as
observed in this patient [25, 26]. However, the distinct
pathophysiological role and the interrelationship between
GLP1, GLP-1 receptors, and hyperplasia of Brunner’s glands
remain to be determined.
Christ et al. speculated in 2009 that Brunner’s glands
may explain the false-positive result in GLP-1 receptor
imaging due to the close location of a lesion to the pancreatic
head [27]. To the best of our knowledge, this is the first
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histologically proven GLP-1R-mediated uptake of 68Ga-
DOTA-Exendin-4 in duodenal Brunner’s gland hyperplasia
detected with PET/CT (Figure 1). More importantly, im-
munohistochemistry of Brunner’s glands was negative for
insulin (Figure 1(e)), suggesting that hyperplasia of Brun-
ner’s glands is not related to autonomous insulin secretion in
this patient. However, the relatively high GLP-1 levels ob-
served in this patient compared to other published data [14]
may be related to the clinical presentation and/or the hy-
perplasia of Brunner’s glands. Generally, hyperplasia of
Brunner’s glands is reported to occur in response to an acidic
environment or Helicobacter pylori infection and can even
be obstructive [28]. However, in this patient, the remainder
of the histological examination did not find any signs of
inflammation or H. pylori colonization. (e exact factor
leading to Brunner’s gland hyperplasia remains to be de-
termined. In addition, whether these changes are critical for
the occurrence of postprandial hypoglycaemia after bypass
surgery needs to be evaluated.
4. Conclusions
(is case indicates a potential relationship between gastric
bypass surgery, PBH, GLP-1, GLP-1R, and Brunner’s glands.
Further investigation is warranted to identify the role of
GLP-1 receptors in Brunner’s glands in patients after
bariatric surgery and specifically in those affected by post-
bariatric hypoglycaemia.
GLP-1 receptor-positive Brunner’s glands are an im-
portant differential diagnosis of positive 68Ga-DOTA-
Exendin-4 PET/CT and a possible pitfall for the location of
insulinomas.
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Figure 1: (a) Glucose (black circles) and total GLP-1 (red dashed lines) plasma levels (measured byMercodia AB, Uppsala, Sweden (assay # 10-
1278-01) of the patient during a standardized mixed-meal test 300ml Ensure plus®, Abbott, containing 60 g carbohydrates). (e patientdeveloped symptomatic hypoglycaemia at a timepoint of 120min (2.5mmol/l) requiring intravenous glucose administration with immediate
resolution of symptoms. (b) Representative 68Ga-DOTA-Exendin-4 PET/CT image of the patient with a large and strong tracer accumulation
(SUVmax 10) in pars 2 duodenii (white arrow). (c) Haematoxylin and eosin staining of a representative duodenal biopsy at 100x resolution
showing hyperplastic Brunner’s glands with (d) GLP-1 receptor immunostaining of Brunner’s glands (membranous distribution) and (e)
negative immunostaining for insulin each at 200x resolution. All staining was performed with a respective positive control (data not shown).
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